Clinical Characteristics and Treatment Outcomes in Ovarian Carcinosarcoma: A Retrospective Cohort Study of 90 Cases Authors: Shihan Wan, Li Yang, Beier Wu, Jingfang Liu, Yiping Jin, Jie Xing, Jiejie Zhang, Aijun Yu Published: 2026 ABSTRACT AbstractObjectiveOvarian carcinosarcoma is a rare and highly aggressive subtype of ovarian cancer. This cohort study aimed to examine clinicopathological features, treatment patterns, and survival outcomes to enhance clinical practice and guide future research.DesignWe conducted a retrospective study of 90 patients diagnosed with ovarian carcinosarcoma between 2006 and 2020.Patients and MethodsDemographic, clinical, histopathological, and treatment-related data were systematically collected and summarized. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan–Meier methods and Cox proportional hazards models.ResultsThe median age at diagnosis was 58 years, and 27.8% of patients had a family cancer history. Most patients were diagnosed at advanced FIGO stages III/IV (81.1%), underwent primary cytoreductive surgery (85.6%), and received adjuvant chemotherapy (95.6%, with 98.8% of these treated using platinum-based chemotherapy). During follow-up, 57.8% patients experienced their first recurrence, and 74.4% died. Multivariable survival analysis indicated that absence of a family cancer history, undergoing primary cytoreductive surgery (PCS), and receiving more than three cycles of adjuvant chemotherapy were independently associated with improved PFS. Earlier FIGO stages, primary cytoreductive, and a platinum-free interval (PFI) longer than six months were significantly associated with longer OS. Among patients with the first recurrence, undergoing secondary cytoreductive surgery (SCS) was associated with significantly improved OS.ConclusionThe retrospective study confirms the frequent late-stage diagnosis and aggressive nature of ovarian carcinosarcoma. Our findings highlight the importance of a negative family cancer history, optimal PCS, sufficient chemotherapy, prolonged PFI, and SCS in improving patient survival. This research bridges critical knowledge gaps and contributes to improving therapeutic strategies for this rare and lethal malignancy.Keywords: ovarian carcinosarcoma, cytoreduction surgery, adjuvant chemotherapy, progression-free survival, platinum-free interval Introduction Ovarian carcinosarcoma, also known as malignant mixed Müllerian tumors or malignant mixed mesodermal tumors, accounts for approximately 1–4% of all ovarian cancer cases.1 It is considered to be one of the rarest and most lethal subtypes of primary ovarian cancer. This aggressive malignancy is characterized by the presence of both malignant epithelial (carcinomatous) and mesenchymal (sarcomatous) components.2 The biphasic nature of ovarian carcinosarcoma contributes to its highly aggressive clinical course and resistance to conventional therapies, distinguishing it from other ovarian cancer subtypes.3,4 Despite advancements in the treatment of ovarian cancer, the diagnosis and management of ovarian carcinosarcoma remain formidable challenges. Clinically, most patients are diagnosed at an advanced stage due to the rapid progression of the disease, with the majority experiencing recurrence within the first year of initial treatment.5–7 Consequently, the overall prognosis is often poor. Given the rarity of ovarian carcinosarcoma, the current literature is predominantly limited to small-scale retrospective studies or isolated case reports, with a notable lack of large-scale retrospective clinical studies.3,5,8–10 In the absence of disease-specific clinical data, treatment of ovarian carcinosarcoma primarily follows the therapeutic paradigm for epithelial ovarian cancer. As a result, therapeutic decisions are relied on clinical experience for epithelial ovarian cancer, anecdotal evidence, or limited retrospective published series. Aggressive surgical cytoreduction remains the cornerstone of treatment, followed by adjuvant chemotherapy for advanced-stage disease.3,8–11 Further research is critical to developing evidence-based, more effective disease-specific therapeutic strategies. This retrospective study analyzed data from 90 patients diagnosed with ovarian carcinosarcoma at our institution between 2006 and 2020. We aimed to comprehensively delineate their demographic and clinicopathological characteristics, summarize treatment patterns, and perform survival analyses. These findings are expected to provide evidence-based insights to guide and optimize the clinical management of this rare and aggressive malignancy. Materials and Methods This study was approved by the Institutional Review Board of Zhejiang Cancer Hospital. We retrospectively recruited a total of 90 patients diagnosed with ovarian carcinosarcoma at Zhejiang Cancer Hospital between September 2006 and December 2020. Histopathological diagnoses were independently reviewed and confirmed by two gynecological pathologists. Detailed clinical data for each patient were extracted from the patients’ electronic database at Zhejiang Cancer Hospital. Ovarian carcinosarcoma is characterized by the presence of both carcinomatous epithelial and sarcomatous (mesenchymal) components (Supplementary Figures S1a–S1d). Staging of the disease was performed according to the International Federation of Gynecology and Obstetrics (FIGO) criteria. For survival analysis, progression-free survival (PFS) was calculated as the time from the date of surgery or the initiation of neoadjuvant chemotherapy to the date of documented disease recurrence. Overall survival (OS) was defined as the time from the date of surgery or the initiation of neoadjuvant chemotherapy to the date of death or the last follow-up date (censored). Statistical Analysis Descriptive data were presented as frequencies and percentages. The Kaplan–Meier method was applied to generate survival curves, as well as the 3- and 5-year survival rates and median survival time. Differences between groups were assessed using the Log-rank test. Cox proportional hazards models were employed to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). A logistic regression model was utilized to assess the association between sufficient chemotherapy and the likelihood of achieving a platinum-free interval (PFI) > 6 months. All P values were two-sided, with a P value of less than 0.05 considered statistically significant. Statistical analysis was performed via the Statistical Package for the Social Sciences (version 22.0; SPSS Inc., Chicago, IL, USA). Results Baseline Characteristics of Patients with Ovarian Carcinosarcoma The median age at diagnosis was 58 years (range, 40–86 years) (Table 1). The most common symptom reported was bloating, occurring in 56.7% of cases, followed by a pelvic mass (18.9%), abdominal pain (10.0%), irregular vaginal bleeding (8.2%), and altered stool consistency (1.2%). At the time of diagnosis, the majority of patients (92%) were postmenopausal, while only 3.3% (n=3) were nulliparous. A family history of cancer was reported in 27.8% (n=25) of the cohort (Table 1). Table 1Characteristics of Patients with Ovarian Carcinosarcoma (N= 90)Characteristicsn (%)Age (years) Median (range)58 (40–86) Group ≤6036 (40) >6054 (60)Presenting symptoms Bloating51 (56.7) Pelvic mass17 (18.9) Abdominal pain9 (10.0) Irregular vaginal bleeding7 (7.8) Change in stool form1 (1.1) Unknown5 (5.6)Menopausal status Postmenopausal81 (90) Premenopausal7 (7.8) Unknown2 (2.2)Parity Nulliparous3 (3.3) Parous87 (96.7)Family history of cancer No65 (72.2) Yes*25 (27.8)Pretreatment CA125 (U/mL)706.9 ± 969.1 ≤356 (6.7) >3560 (66.7) Unknown24 (26.7)Median tumor size (cm)9.6 (range, 3.0–22.0)FIGO stage I6 (6.7) II11 (12.2) III53 (58.9) IV20 (22.2)Ascites No45 (50) Yes45 (50)Malignant cells found in ascites or peritoneal lavage fluid No31 (34.4) Yes25 (27.8) Unknown34 (37.8)First recurrence52 (57.8)Overall death (OS)67 (74.4%)Notes: *Detailed cancer sites (number): Gastric cancer (5), lung cancer (4), colorectal cancer (4), liver cancer (4), ovarian cancer (2), cervical cancer (2), esophageal cancer (2), and bone marrow cancer (2).Abbreviation: FIGO, International Federation of Gynecology and Obstetrics. Characteristics of Patients with Ovarian Carcinosarcoma (N= 90) Notes: *Detailed cancer sites (number): Gastric cancer (5), lung cancer (4), colorectal cancer (4), liver cancer (4), ovarian cancer (2), cervical cancer (2), esophageal cancer (2), and bone marrow cancer (2). Abbreviation: FIGO, International Federation of Gynecology and Obstetrics. Tumor sizes varied widely, with a median diameter of 9.6 cm (range, 3.0–22.0 cm). According to the FIGO staging system, patient distribution was as follows: 6.7% stage I (n = 6), 12.2% stage II (n = 11), 58.9% stage III (n = 53), and 22.2% stage IV (n = 20). The mean pretreatment CA125 level was 706.9 ± 969.1 U/mL, with 6 patients (9.1%) having CA125 levels below 35 U/mL. Ascites was present in 50% of patients (n = 45), and malignant cells were detected in ascites or peritoneal washings in 27.8% of patients (n= 25). At the end of the study, 52 patients experienced recurrence, and 67 patients died (Table 1). Treatment Modalities Among the patients studied, 77 (85.6%) underwent primary cytoreductive surgery (PCS), and 13 (14.4%) received neoadjuvant chemotherapy followed by interval cytoreductive surgery (NACT/ICS) (Table 2). All patients underwent hysterectomy and salpingo-oophorectomy. Additionally, 85 patients (94.4%) underwent omentectomy, and 72 patients (80%) underwent para-aortic or pelvic lymphadenectomy. Appendectomy was performed in 33 patients (36.7%), bowel resection in 21 patients (23.3%), colostomy in 13 patients (14.4%), partial hepatectomy in 8 patients (8.9%), and splenectomy in 6 patients (6.7%) (Table 2). Of these patients, 62 (68.9%) achieved no residual disease, 20 patients (22.2%) had residual disease ≤ 1 cm, 3 patients (3.3%) had residual disease of 2 cm, and the status of 5 patients remained unknown. Para-aortic/pelvic lymphadenectomy was performed on 72 patients (80.0%). Among these, 25 patients (34.7%) had para-aortic/pelvic lymph node metastasis (Table 2). Table 2Treatment Modalities for Patients with Ovarian CarcinosarcomaVariablen (%)Primary treatment before recurrence Primary cytoreductive surgery (PCS)77 (85.6) Neoadjuvant chemotherapy followed by interval debulking surgery (NACT/ICS)13 (14.4)Surgical procedures performed Salpingo-oophorectomy90 (100) Hysterectomy90 (100) Omentectomy85 (94.4) Para-aortic/pelvic lymphadenectomy72 (80) Appendectomy33 (36.7) Bowel resection21 (23.3) Colostomy13 (14.4) Partial hepatectomy8 (8.9) Splenectomy6 (6.7)Residual disease after surgery No62 (68.9) ≤1 cm20 (22.2) 2 cm3 (3.3) Unknown5 (5.6)Para-aortic/pelvic lymphadenectomy No15 (16.7%) Yes72 (80.0) Unknown3 (3.3)Para-aortic/pelvic lymph nodes metastasis No47 (52.2) Yes25 (27.8) Unknown18 (20)Adjuvant chemotherapy No2 (2.2) Yes86 (95.6) Unknown2 (2.2)Chemotherapy regime Platinum-based chemotherapy85 (98.8) Non-platinum-based chemotherapy1 (1.2) Platinum-based chemotherapy Platinum and taxane81 (95.3) Ifosfamide and cisplatin3 (3.5) Liposomal, doxorubicin and carboplatin1 (1.2)Number of adjuvant chemotherapy cycles 0–320 (22.2) 4–868 (75.6)Progression free interval (PFI) ≤ 6 months24 (26.7) > 6 months56 (62.2) Unknown10 (11.1)Treatment approach after first relapse Secondary cytoreductive surgery (SCS)27 (51.9) Chemotherapy23 (44.2) Unknown2 (3.8)Residual disease after secondary cytoreductive surgery (SCS) No19 (70.4) ≤ 1 cm2 (7.4) > 1 cm1 (3.7) Unknown5 (18.5)Abbreviations: NACT/ICS, neoadjuvant chemotherapy followed by interval cytoreductive surgery; PCS, primary cytoreductive surgery; PFI, platinum-free interval; SCS, secondary cytoreductive surgery. Treatment Modalities for Patients with Ovarian Carcinosarcoma Abbreviations: NACT/ICS, neoadjuvant chemotherapy followed by interval cytoreductive surgery; PCS, primary cytoreductive surgery; PFI, platinum-free interval; SCS, secondary cytoreductive surgery. In line with the “ultraradical” surgery approach recommended by the UK National Institute for Health and Care Excellence for patients with advanced ovarian malignancies,10 we implemented this surgery in a subset of patients. Of the patients who underwent surgery, 29 met the criteria for “ultraradical” procedures, all of whom had advanced-stage ovarian carcinosarcoma. Among these, 19 patients (65.5%) underwent diaphragmatic surgery, 11 (37.9%) had multiple bowel resections, 7 (24.1%) underwent splenectomy, and 7 (24.1%) had hepatic lesion resection. Additionally, 2 patients (6.9%) underwent high-level lymphadenectomy, including resection of lymph nodes above the renal vein and/or cardiophrenic angle nodes. One patient (3.4%) underwent partial gastrectomy (Supplementary Table S1). Adjuvant chemotherapy was administered to 86 patients (95.6%), with 68 patients (79.1%) completing 4–8 cycles. The vast majority (98.8%) of patients were treated with platinum-based regimens. Of these, 81 patients (95.3%) received platinum and taxane combination therapy, while 3 patients (3.5%) were treated with ifosfamide and cisplatin, and 1 patient (1.2%) received a combination of liposomal doxorubicin and carboplatin. Additionally, 4 patients who received platinum-based chemotherapy were also treated with bevacizumab every three weeks for 5–13 doses. Only one patient received a non-platinum-based chemotherapy regimen consisting of ifosfamide and paclitaxel (Table 2). Recurrences and Survival Outcomes Disease recurrence was observed in 52 patients (57.8%), with recurrence sites documented in 49 of these cases. The initial recurrence sites were distributed as follows: 34.7% pelvic (n=17), 16.3% abdominal (n=8), 14.3% combined abdominopelvic (n=7), 18.4% extra-abdominopelvic (n=9), and 16.3% both abdominopelvic plus extra-abdominopelvic (n=8) locations. Among the extra-abominopelvic sites, recurrences were observed in 7 cases (14.3%), lungs in 3 cases (6.1%), supraclavicular lymph nodes in 2 cases (4.1%), cardiophrenic lymph nodes in 2 cases (4.1%), and one case each (2.0%) in the inguinal lymph nodes, spleen, abdominal wall, and thigh (Supplementary Table S2). Among patients who experienced recurrence, 27 patients underwent secondary cytoreductive surgery (SCS), while 23 received chemotherapy alone. Among those who underwent SCS, 19 patients had no visible residual disease, 2 patients had ≤ 1 cm residual disease, and 1 patient had > 1 cm residual disease. Of the patients who underwent SCS, 18 developed a second recurrence. Tertiary debulking surgery was performed in 11 patients (61.1% of second recurrences), and optimal cytoreduction (residual disease ≤ 1 cm) was achieved in 2 patients. Ultimately, 7 patients (63.6% of third debulking surgeries) progressed to a third recurrence (Supplementary Figure S2). The Kaplan–Meier survival analysis revealed that the 2- and 5-year PFS rates were 54.0% and 27.4%, respectively. The median PFS was 26.0 months (95% CI: 20.6–31.4) (Supplementary Figure S3a and Table 3). The 2- and 5-year OS rates were 71.0% and 46.6%, respectively. The median overall survival was 48.0 months (95% CI: 25.4–70.6) (Supplementary Figure S3b and Table 3). Table 3Survival Rates of Patients with Ovarian CarcinosarcomaVariablePFSOSSurvival Rate (%)Median SurvivalTime (Months)Survival Rate (%)Median SurvivalTime (Months)2-Year5-Year2-Year5-YearAll patients54.027.426.0 (20.6–31.4)71.046.648.0 (25.4–70.6)Family history No62.931.928.0 (2.7–22.7)79.746.831.9 (0–112.4) Yes31.410.521.4 (5.4 −10.8)56.043.217.2 (0–62.7)FIGO stage I/II53.331.131.9 (0–71.5)82.357.4 III/IV54.426.826 (20.3–29.9)68.341.339.0 (27.2–50.8)Surgery PCS54.629.426.4 (20.1–32.7)73.750.454.0 (0.9–107.1) NACT/ICS28.6020.0 (6.1–33.9)51.317.125.0 (21.7–28.3)Adjuvant chemotherapy ≤ 3 cycles26.617.711.0 (1.0–21.1)50.022.524.0 (8.7–39.3) > 3 cycles55.728.826.4 (22.1–30.7)79.054.365.0 (9.2–120.8)PFI ≤ 6 months50.012.524.0 (20.1–27.9) > 6 months84.444.650.0 (33.2–66.9)SCS Yes81.553.765.0 No56.519.129.0 (12.34–45.66)Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; NACT/ICS, neoadjuvant chemotherapy followed by interval cytoreductive surgery; PCS, primary cytoreductive surgery; PFI, platinum-free interval; OS, overall survival; SCS, secondary cytoreductive surgery. Survival Rates of Patients with Ovarian Carcinosarcoma Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; NACT/ICS, neoadjuvant chemotherapy followed by interval cytoreductive surgery; PCS, primary cytoreductive surgery; PFI, platinum-free interval; OS, overall survival; SCS, secondary cytoreductive surgery. Impact of Clinicopathological Factors on PFS or OS in Patients with Ovarian Carcinosarcoma A family history of cancer was significantly associated with shorter median PFS (21.4 vs 28.0 months for no family history, P=0.016) (Figure 1a and Table 3), but not significantly correlated with OS (P = 0.355) (Figure 1b and Table 3). The FIGO stage was not significantly associated with PFS (P = 0.625) or OS (P=0.119) (Figures 1c, d, and Table 3). Patients who underwent PCS had significantly better PFS and OS outcomes than did those who received NACT/ICS. The median PFSs were 26.4 and 20.0 months for the PCS group and the NACT/ICS group (P = 0.049), respectively (Figure 1e and Table 3). Moreover, the median OS was 50.4 months for the PCS group compared with 17.1 months for those who received NACT/ICS (P = 0.005) (Figure 1f and Table 3). Kaplan‒Meier survival curves illustrating the impact of various clinical factors on progression-free survival (PFS) and overall survival (OS) in patients with ovarian carcinosarcoma.PFS (a) and OS (b) stratified by family history; PFS (c) and OS (d) by the FIGO stage. PFS (e) and OS (f) by treatment group (PCS vs. NACT/ICS); PFS (g) and OS (h) by number of adjuvant chemotherapy cycles (≤3 vs. >3). continued. Additionally, patients who received ≤ 3 cycles of adjuvant chemotherapy had significantly shorter median PFS (11.0 months) compared with > 3 cycles group (26.4 months) (P = 0.033) (Figure 1g and Table 3), and the median OS was 65 months for the > 3 cycles group, which was significantly better than that of the ≤ 3 cycles group (24.0 months) (P = 0.015) (Figure 1h and Table 3). Residual disease did not show a significant association with PFS (P = 0.320) (Supplementary Figure S4a) or OS (P = 0.285) (Supplementary Figure S4b). Likewise, ultraradical surgery did not have an impact on PFS (P = 0.491) (Supplementary Figure S4c) or OS (P = 0.802) (Supplementary Figure S4d). The PFI was defined as the period from the last dose of a platinum-based chemotherapy drug to the date of cancer recurrence or progression. Our logistic regression analysis indicated that patients receiving sufficient chemotherapy (> 3 cycles) had a higher likelihood of achieving a PFI > 6 months (Supplementary Table S3). PFI of ≤ 6 months after initial treatment had a significantly lower median OS than did those with an interval of >6 months (24.0 months vs. 50.0 months, P < 0.001) (Figure 2a and Table 3). SCS was associated with improved median OS (OS) (65.0 months vs. 29 months after the first recurrence, P = 0.007) (Figure 2b and Table 3). Kaplan–Meier overall survival (OS) curves in patients with ovarian carcinosarcoma stratified by platinum-free interval (PFI) time (months) (a) and receipt of secondary cytoreductive surgery (SCS) (b). Multivariate Analysis of Factors Associated with Survival Outcomes In the multivariable analysis of PFS, a family history of cancer was significantly correlated with poorer PFS (HR=2.9, 95% CI: 1.6–5.5, P=0.001). Conversely, optimal PCS was significantly associated with improved PFS (HR=0.3, 95% CI: 0.1–0.7, P=0.005). Similarly, receiving sufficient adjuvant chemotherapy (> 3 cycles) was significantly associated with better PFS (HR=0.3, 95% CI: 0.1–0.7, P=0.005) (Table 4). Table 4Univariable and Multivariable Survival Analysis of PFS and OS in Patients with Ovarian CarcinosarcomaVariablePFSOSUnivariableMultivariableUnivariableMultivariableHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P valueAge (years) Continuous0.4 (1.0–1.0)0.6351.02 (0.99–1.05)0.313 Group ≤ 6011 >600.7 (0.4–1.4)0.3070.6 (0.3–1.1)0.092Family history No11 Yes2.0 (1.1–3.5)0.0182.9 (1.6–5.5)0.0011.3 (0.7–2.4)0.359CA125 (U/mL) ≤3511 >350.8 (0.3–2.0)0.6001.3 (0.4–3.6)0.654Ascites No11 Yes0.8 (0.5–1.4)0.5211.3 (0.7–2.2)0.361FIGO stage I/II111 III/IV0.8 (0.4–1.7)0.6271.9 (0.8–4.1)0.1272.8 (1.1–7.3)0.035Surgery NACT/ICS1111 PCS0.5 (0.2–1.0)0.0560.3 (0.1–0.7)0.0050.4 (0.2–0.8)0.0070.4 (0.2–0.9)0.020Ultraradical surgery No11 Yes0.8 (0.5–1.5)0.4931.1 (0.6–1.9)0.803Tumor size (cm) ≤ 9.611 > 9.61.0 (0.5–2.0)0.9140.9 (0.4–1.9)0.776Residual disease No11 Yes1.4 (0.7–2.5)0.3231.4 (0.8–2.5)0.290Para-aortic/pelvic lymphadenectomy No111 Yes0.6 (0.3–1.1)0.1020.5 (0.3–1.0)0.0410.5 (0.3–1.1)0.102Adjuvant chemotherapy ≤ 3 cycles11 >3 cycles0.5 (0.2–1.0)0.0380.3 (0.1–0.7)0.0050.5 (0.3–0.9)0.018PFI ≤ 6 months11 > 6 months0.2 (0.1–0.3)<0.0010.1 (0.04–0.18)<0.001SCS No1 Yes0.4 (0.2–0.8)0.011Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; NACT/ICS, neoadjuvant chemotherapy followed by interval cytoreductive surgery; OS, overall survival; PCS, primary cytoreductive surgery; PFI, platinum-free interval; SCS, secondary cytoreductive surgery. Univariable and Multivariable Survival Analysis of PFS and OS in Patients with Ovarian Carcinosarcoma Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; NACT/ICS, neoadjuvant chemotherapy followed by interval cytoreductive surgery; OS, overall survival; PCS, primary cytoreductive surgery; PFI, platinum-free interval; SCS, secondary cytoreductive surgery. Multivariable analysis of OS revealed that optimal PCS (HR=0.40, 95% CI: 0.2–0.9, P=0.020) and a prolonged PFI (HR=0.5, 95% CI 0.04–0.18, P<0.001) were significantly associated with better OS. In contrast, advanced FIGO (HR=2.8, 95% CI: 1.1 −7.3, P=0.035) was significantly associated with worse OS. Additionally, para-aortic/pelvic lymphadenectomy showed a marginal association with improved OS (HR=0.5, 95% CI: 0.3–1.1, P=0.102) (Table 4). Discussion Ovarian carcinosarcoma, a rare and aggressive gynecologic malignancy, remains poorly characterized with no standardised treatment protocols. This retrospective cohort study examined 90 patients with ovarian carcinosarcoma. Our findings indicated that patients were typically diagnosed at an older age and in advanced stages of the disease. Half of the patients presented with ascites, and nearly a quarter showed pelvic and para-aortic lymph node metastasis. Up to 58% patients developed recurrences after initial treatments, and 74.4% of them had died at the end of the study. A family history of cancer, optimal PCS, and sufficient chemotherapy were associated with patients’ prognosis. Notably, patients who achieved a PFI of over six months demonstrated better overall survival (OS). Furthermore, SCS was linked to improved OS for those who experienced a first recurrence. Our study presents important characteristics of ovarian carcinosarcoma and provides valuable clinical evidence to advise management strategies for this aggressive and challenging malignancy. The FIGO staging system, originally developed for epithelial ovarian cancer, is currently applied to stage ovarian carcinosarcoma.5 Consistent with prior studies,2–4,12 we found that up to 81.1% of patients with ovarian carcinosarcoma were diagnosed at FIGO stages III or IV. Other additional case reports further corroborate frequent late-stage diagnoses.13,14 Although we found no significant correlation between FIGO stage and PFS, advanced FIGO stage was independently associated with poorer OS after adjusting for other prognostic factors. A recent study of 79 patients (17 with stage I/II, 62 with stage III/IV) reported significantly better OS for stage I/II patients compared to those with stage III disease (HR = 0.48, 95% CI: 0.27–0.87, P = 0.015).3 Another study reported a significant association between FIGO stage and OS in a multivariate analysis of patients with ovarian carcinosarcoma.15 In contrast, an earlier study conducted two decades ago reported no such association.5 Collectively, emerging evidence increasingly supports the prognostic value of the FIGO staging system in ovarian carcinosarcoma. The frequent diagnosis at advanced stages further underscores the urgent need for effective early detection strategies. It is estimated that approximately 10–15% of ovarian cancers (including fallopian tube and primary peritoneal cancers) are associated with hereditary factors.8 Prior studies have explicitly linked BRCA1/2 germline pathogenic variants to ovarian cancer.16,17 Inherited mutations in genes like BRCA1 and BRCA2 are implicated in hereditary ovarian cancer syndrome, characterized by a significantly increased susceptibility to ovarian cancer and multiple primary tumors, and familial clustering of malignancies.9 Family histories of cancer have been observed in patients with ovarian carcinosarcoma.13,14,18 In our current study, 25 patients (27.8%) had a family history of cancer. These patients exhibited a shorter median PFS compared to those without a family history. However, there was no significant difference in overall survival (OS) between the two groups. While we did not examine the genetic information in our patients, previous studies reported BRCA1/2 germline pathogenic variants in ovarian carcinosarcoma.13,14,18 These findings imply that hereditary genetic factors may contribute to the development of the disease, implying a potential of genetic counseling in identifying individuals at elevated risk. Comprehensive molecular profiling of ovarian carcinosarcoma could help elucidate the underlying molecular mechanisms driving its onset and progression, as well as identify markers for future targeted therapies. PCS followed by adjuvant chemotherapy is the traditional first-line treatment approach for advanced epithelial ovarian cancer, with the primary objective of achieving maximal removal of visible tumor burden.19 In contrast, NACT/ICS begins with chemotherapy to reduce tumor burden before the surgical intervention to excise the remaining tumor.20 Earlier observational studies suggested that PCS offered a survival advantage over NACT/ICS for patients with advanced epithelial ovarian cancer.20,21 The TRUST, an international randomized multicenter Phase III trial, compared the efficacy of PCS followed by chemotherapy (n = 345) with NACT/ICS (n = 343) in patients with FIGO IIIB-IVB epithelial ovarian cancer. Their results demonstrated that PCS followed by intravenous chemotherapy led to significantly longer median PFS and a trend toward improved OS in non-frail patients.22 Less favorable survival outcomes associated with neoadjuvant chemotherapy followed by interval cytoreductive surgery (NACT/ICS) have been linked to an increased risk of developing platinum resistance. This resistance may arise due to several factors: (1) inaccurate visual assessment of tumor burden during ICS, leading to incomplete resection and residual disease; (2) chemotherapy-induced transformation of cancer cells into a more stem-like phenotype, contributing to increased tumor aggressiveness; and (3) the emergence of mutations that promote chemoresistance.23 As a result, NACT/ICS was generally reserved for highly selected patients with unresectable disease or poor performance status.23 Despite these findings, a trend study indicated that NACT/ICS has become the predominant upfront treatment for advanced epithelial ovarian cancer since 2021, particularly among patients with stage IV disease, with increased utilization across all stages and age groups.24 A recent meta-analysis of randomized controlled trials (RCTs) involving women with advanced epithelial ovarian cancer (FIGO stage III/IV) reported little or no difference in OS and likely little or no difference in PFS between patients treated with PCS versus those receiving NACT/ICS.25 In our study, 77 patients (85.6%) underwent PCS, while 13 (14.4%) received NACT/ICS. Patients who underwent PCS achieved better PFS and OS outcomes compared to those treated with NACT/ICS. Further studies with larger cohorts are essential to validate the potential superiority of PCS in managing ovarian carcinosarcoma. Achieving optimal PCS, which is defined as the complete removal of all visible tumor, remains a primary therapeutic goal in advanced ovarian cancer and is strongly associated with improved survival outcomes, making it a key prognostic indicator.26 In our study, 62 patients (68.9%) had no residual disease after the surgery, 20 patients (22.2%) had residual tumors measuring ≤ 1 cm, and only 3 cases (3.3%) had 2 cm of residual disease (suboptimal). Overall, 91.1% of patients achieved optimal debulking surgery. Survival analysis indicated that patients with no residual disease did not show a significant difference in PFS or OS compared to those who had residual disease. The small number of patients with non-optimal debulking limited our ability to compare their survival outcomes with those in the optimal debulking group. Our results suggest patients with optimal debulking with residual tumor ≤ 1 cm may have comparable survival compared to those who had no residual disease. These findings are similar to those of Rauh-Hain et al,27 who reported optimal cytoreduction (no or residual tumor ≤ 1 cm) were significantly associated with improved OS compared to those with suboptimal debulking (residual tumor > 1 cm) in a multivariable survival analysis Another study reported 30 of 79 (38%) patients with ovarian carcinosarcoma achieved no visible residual disease, while the remaining 49 (62%) had either < 2 cm or ≥ 2 cm residual disease after debulking surgery. Although residual disease ≤ 1 cm was not specifically detailed, their multivariable analysis demonstrated a significant survival advantage for those with no visible disease.3 Other studies have similarly confirmed the survival benefit associated with no residual tumor or optimal debulking surgery in ovarian carcinosarcoma.4,28,29 These findings, along with our study, highlight the critical role of achieving optimal PCS or even no residual tumor in improving survival outcomes for patients with ovarian carcinosarcoma. Ultraradical surgery or maximal-effort cytoreduction surgery involves additional complex surgical procedures such as splenectomy, multiple bowel resections, diaphragm stripping, and resection of porta hepatis nodal disease.30 These interventions aim to remove all visible cancer. In our cohort of 90 patients with ovarian carcinosarcoma, 29 underwent ultraradical surgery. We observed no significant association between ultraradical surgery and PFS or OS. One possible explanation is that the majority of our patients, regardless of surgical approach, achieved optimal cytoreduction, potentially diminishing differences in survival outcomes between those who underwent ultraradical versus standard cytoreductive procedures. This observation aligns with findings from broader ovarian cancer populations, where the survival benefit of ultraradical surgery remains inconsistent.30–32 Consequently, the role of ultraradical surgery in managing ovarian carcinosarcoma remains uncertain and warrants further investigation. The main treatment for ovarian carcinosarcoma involves cytoreductive surgery followed by platinum-based chemotherapy. The two most commonly used chemotherapy regimens are platinum–ifosfamide and platinum–taxane. However, the efficacy of these regimens remains inconclusive.33,34 In our study, the vast majority (98.8%) of patients received platinum-based regimens. Of these, 81 patients (95.3%) were treated with a platinum and taxane combination therapy, while 3 patients (3.5%) received ifosfamide and cisplatin. Due to the small number of patients in the ifosfamide-cisplatin group, we were unable to effectively compare the efficacy between platinum–ifosfamide and platinum–taxane. Additionally, our results showed that patients who received more than three cycles of adjuvant chemotherapy demonstrated significantly longer median progression-free survival (PFS) compared to those who received three or fewer cycles (26.4 months vs. 11.0 months, P = 0.033). This result is consistent with findings from another study, which reported a significantly higher 5-year recurrence-free survival rate for patients receiving six cycles of chemotherapy compared to those receiving three cycles in cases of serous carcinoma (82.7% vs. 60.4%, P = 0.007).35 Our data reinforce that both the duration of chemotherapy (> 3 cycles) and the use of platinum-based agents are critical for optimizing outcomes for patients with ovarian carcinosarcoma. The PFI classification system, introduced by Markman et al36 in 1991, categorizes recurrent ovarian cancer into platinum-resistant (PFI ≤ 6 months) or platinum-sensitive (PFI > 6 months). Its prognostic role is well established in epithelial ovarian cancer,37,38 yet its applicability to rare histologic subtypes such as ovarian carcinosarcoma remains underexplored. Our study explored the prognostic utility of PFI in patients with ovarian carcinosarcoma. Stratified analysis revealed significantly shorter median OS in patients with PFI ≤ 6 months (24.0 months) compared to those with PFI > 6 months (54.0 months, P = 0.001). Multivariable survival analysis confirmed that PFI was an independent prognostic factor for OS. Furthermore, our data revealed that receiving more than 3 cycles of chemotherapy was significantly associated a PFI > 6 months, suggesting that sufficient chemotherapy is essential for achieving platinum sensitivity and improving survival outcomes. Interestingly, PFI as a surrogate marker of platinum-sensitivity, may help identify patients who are more likely to benefit from second-line chemotherapy.12 These findings strongly support integrating platinum sensitivity stratification into ovarian carcinosarcoma management algorithms. Similar to patients with epithelial ovarian cancer, those with ovarian carcinosarcoma often experience recurrences following initial treatments. Effective management of these recurrences is crucial to improve their survival. However, no standard second-line treatment has been validated for relapsed ovarian carcinosarcoma. In our cohort of 90 patients, 52 (57.8%) experienced the first recurrence with a median recurrence time of 26 months. Our data found that SCS conferred a remarkable survival advantage for those recurrent patients (a median OS of 65 months vs only 29 months for the non-SCS group, P = 0.007). This result aligns with the findings from the SOC-1 trial, which showed that the SCS group demonstrated significantly longer median PFS than the non-SCS group (17.4 months vs. 11.9 months, P < 0.0001) in patients with platinum-sensitive relapsed ovarian cancer.39 Another study also reported a survival advantage when SCS was combined with the targeted therapy in the treatment of platinum-sensitive recurrent ovarian cancer.11 Collectively, these results supported the use of SCS in the treatment of patients with first recurrences. Conversely, among 52 patients who experienced the first recurrence, 23 (44.2%) developed a second recurrence. In this subgroup, tertiary debulking surgery did not show a significant survival benefit. Given the limited sample size, the role of tertiary debulking surgery in second recurrent carcinosarcoma remains uncertain and warrants further investigation. Limitations of the study include its retrospective nature and potential bias in patient selection. The sample size is moderate and may limit the generalizability of the findings. Additionally, the sarcoma components and molecular histological subtypes were not further classified, restricting insights into their prognostic impact. The baseline patient condition prior to treatment was not well documented, making it unclear whether it influenced treatment selection or outcomes. Furthermore, only pretreatment serum CA125 levels were analyzed; monitoring changes in dynamic CA125 during treatment could have clarified its role as a biomarker for disease progression and response to therapy, but it was not included in the study. As the majority of patients (95.3%) received platinum–taxane regimens, meaningful comparison with other chemotherapy regimens was not feasible. As no patients received radiation therapy, novel immunotherapy, or targeted therapy, the potential role of these treatments could not be evaluated. Despite these limitations, a major strength of this study is the inclusion of 90 patients with ovarian carcinosarcoma, a rare and aggressive malignancy, treated at a tertiary cancer center within the SOC-1 collaborative group. This cohort study provides a robust real-world insight into clinical outcomes and treatment patterns. Conclusions Our findings confirm the predominance of late-stage presentation and the aggressive nature of ovarian carcinosarcoma. We provide important evidence reinforcing the prognostic significance of family cancer history and FIGO stage, as well as the essential roles of PCS, sufficient chemotherapy (more than three cycles), and SCS in the management of this malignancy. Furthermore, validation of the PFI as a prognostic marker offers novel insights and may facilitate in developing personalized chemotherapy strategies. Multicenter collaborative studies are warranted to generate more comprehensive and generalizable evidence to enhance understanding and improve clinical management of this disease. Acknowledgments The authors thank the patients who contributed to the study. The authors also thank their clinical colleagues at Zhejiang Cancer Hospital for their technical assistance, data collection support, and constructive discussions. Funding Statement This work was supported by the National Natural Science Foundation of China (82274266 and 82505319), the Outstanding Young Talent Fund Project of Chinese Medicine of Zhejiang province, China (2022ZQ018), and Zhejiang Province Chinese Medicine Science and Technology Project, China (2024ZL025). Data Sharing Statement The datasets generated during this study are available from Dr. Jiejie Zhang, the corresponding author, on reasonable request. Ethics Approval and Consent to Participate This study was approved by the Medical Ethics Committee of Zhejiang Cancer Hospital (IRB-2021-350 (IIT)). All participants provided written informed consent prior to participation. All methods were performed in accordance with the relevant guidelines and regulations (i.e., Declaration of Helsinki). Disclosure All authors declare that there are no conflicts of interest in this work. References Associated Data Data Availability Statement The datasets generated during this study are available from Dr. Jiejie Zhang, the corresponding author, on reasonable request.